❋
Clinical-Grade iPSC Line Selection Strategy for Cell Therapy Development
About Client
The client is an early-stage human pluripotent stem cell (hPSC)-based cell therapy startup developing allogeneic therapeutic products. The company needed to identify and evaluate commercially available clinical-enabling iPSC lines
Study: Strategic sourcing and technical evaluation framework for clinical-grade iPSC line selection
Challenge
Client requested external expertise to navigate the complex landscape of clinical-grade iPSC suppliers and regulatory requirements
Need for systematic comparison of technical specifications, quality documentation, and commercial terms across multiple vendors
Risk of costly delays (6-12 months) or suboptimal selection affecting quality and safety of product, downstream CMC development, and regulatory timelines
Solution
Conducted comprehensive supplier landscape analysis and technical vetting of qualified clinical-grade iPSC providers
Developed multi-criteria evaluation framework incorporating characterization data, genetic stability, differentiation potential, regulatory compliance, and commercial terms
Evaluated manufacturing capabilities, regulatory track records, and quality systems
Created quantitative decision metrics aligned to client's therapeutic modality, development timeline, and risk tolerance.
Results
The engagement delivered measurable time and cost savings while establishing the foundation for a robust CMC strategy
Accelerated decision-making by >6 months (2 months vs. 8-9 months) with comprehensive, actionable report enabling confident cell line shortlisting
Prevented the evaluation of unsuitable cell lines, saving $150K-300K in unnecessary studies and 4-6 months of experimental work
Established a qualified vendor partnerships with favorable terms and created reusable evaluation framework for future assessments